Publications

Quantifying incidence and pathways across TB disease states following Mtb infection.

HORTON, K; Emery, JC; RICHARDS, AS; Esmail, H; HOUBEN, R;

2022

(2022).

Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment.

Antimycobacterial Susceptibility Testing Group,;

2022

European Respiratory Journal, (2022).59 4 10.1183/13993003.00166-2022.

Estimating the contribution of subclinical tuberculosis disease to transmission – an individual patient data analysis from prevalence surveys.

EMERY, J; Dodd, P; Banu, S; Frascella, B; Garden, F; HORTON, K; Hossain, S; Law, I; Van Leth, F; Marks, G; Nguyen, HB; Nguyen, HV; Onozaki, I; Quelapio, MI; RICHARDS, A; Shaikh, N; Tiemersma, E; WHITE, R; Zaman, K; Cobelens, F; HOUBEN, RM G J;

2022

medRxiv (2022). 10.1101/2022.06.09.22276188.

Re-evaluating pathways through the spectrum of tuberculosis disease following M. tuberculosis infection.

HORTON, K; RICHARDS, AS; Emery, JC; Esmail, H; HOUBEN, RM G J;

2022

(2022).

Early risk assessment in paediatric and adult household contacts of confirmed tuberculosis cases by novel diagnostic tests (ERASE-TB): protocol for a prospective, non-interventional, longitudinal, multicountry cohort study.

Marambire, ET; Banze, D; Mfinanga, A; Mutsvangwa, J; Mbunda, TD; Ntinginya, NE; Celso, K; Kallenius, G; CALDERWOOD, CJ; Geldmacher, C; Held, K; Appalarowthu, T; Rieß, F; Panzner, U; Heinrich, N; KRANZER, K; ERASE-TB Consortium,;

2022

BMJ Open, (2022).12 7 10.1136/bmjopen-2022-060985.

End-point definition and trial design to advance tuberculosis vaccine development.

Garcia-Basteiro, AL; WHITE, RG; Tait, D; Schmidt, AC; Rangaka, MX; Quaife, M; Nemes, E; Mogg, R; Hill, PC; Harris, RC; Hanekom, WA; Frick, M; Fiore-Gartland, A; Evans, T; Dagnew, AF; Churchyard, G; Cobelens, F; Behr, MA; Hatherill, M;

2022

European respiratory review, (2022).31 164 10.1183/16000617.0044-2022.

Elevated Plasma Matrix Metalloproteinase 8 Associates With Sputum Culture Positivity in Pulmonary Tuberculosis.

Walker, NF; Karim, F; Moosa, MY S; Moodley, S; Mazibuko, M; Khan, K; Sterling, TR; Van der Heijden, YF; GRANT, AD; Elkington, PT; Pym, A; Leslie, A;

2022

The Journal of Infectious Diseases, (2022).226 5 10.1093/infdis/jiac160.

TBVAX Model.

CLARK, R; MUKANDAVIRE, C; WEERASURIYA, C; Bakker, R; WHITE, RG;

2022

, Zenodo (2022).

Demonstrating multi-country calibration of a tuberculosis model using new history matching and emulation package - <i>hmer</i>.

Scarponi, D; Iskauskas, A; CLARK, R; Vernon, I; McKinley, T; Goldstein, M; Mukandavire, C; Deol, A; WEERASURIYA, C; Bakker, R; WHITE, R; MCCREESH, N;